Dispatch console / Two-peptide manifest
BPC-157 TB-500 is the two-peptide Wolverine blend, tracked through the research record and the regulatory channel it ships in.
Two distinct peptides on one manifest — BPC-157 in the cytoprotective lane, TB-500 in the cell-migration lane. Every preclinical finding is logged to its source, every blend-level claim carries the honest no-human-data flag.
BPC-157 and TB-500: what the Wolverine pairing actually is
BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides shipped on a single manifest, marketed and discussed under the name "Wolverine." BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide — sequence GEPPPGKPADDAGLV, molecular weight ~1419.5 Da, CAS 137525-51-0 — derived from a partial sequence of a protein found in human gastric juice [1]. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight ~889 Da, corresponding to residues 17-23 of the 43-residue protein Thymosin Beta-4 [7].
The blend has no single molecular weight, no CAS number, and no standardized composition. Commercial research-product vials commonly pair the two at fixed combined masses — for example 10 mg BPC-157 with 10 mg TB-500 — but no peer-reviewed study has defined a validated blend ratio [6]. The two values above describe the two constituents, not a unified entity.
The pairing is rationalized as a two-mechanism tissue-repair manifest. BPC-157 runs the cytoprotective and pro-angiogenic lane: it up-regulates VEGFR2 and drives the VEGFR2-Akt-eNOS pathway [2]. TB-500 runs the cell-migration lane: its LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics behind cell migration [3]. The two lanes are described as complementary — that is the basis of the combination rationale and synergy claim. Whether they actually converge on a greater-than-additive result is unestablished; no controlled combination study has been published.
For the regulatory picture — FDA status and the WADA Prohibited List — see BPC-157 TB-500 regulatory status. For how legally compounded access works, see Wolverine legal status and 503A compounding. What follows on this site is editorial commentary on the published literature, organized as a two-lane manifest you can scan and verify.
The 'Wolverine stack': combination rationale and the synergy claim
The combination rationale is mechanistic complementarity, not a measured result. BPC-157 supplies a local cytoprotective and pro-angiogenic signal through VEGFR2-Akt-eNOS and growth-hormone-receptor-driven fibroblast proliferation [2]. TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal that regulates cell migration and re-epithelialization [3][4]. On paper the two pathways are largely non-overlapping, which is why proponents describe stacking them.
The synergy claim is a theoretical extrapolation from each peptide's separately characterized mechanism. No peer-reviewed study defines a synergistic dose, ratio, or endpoint for the two given together [11]. The most recent systematic review of BPC-157 — 36 studies, only one in humans — makes no mention of TB-500 or any combination [10]. "Synergy" is an inference drawn across two literatures, not a finding lifted from one experiment.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies an actin-sequestration signal driving cell migration [2][3]. The complementarity is theoretical. No controlled combination study has defined a synergistic dose, ratio, or endpoint for the pairing [11].
What this manifest tracks
This page opens the manifest; the rest of the site routes the detail. What the research literature shows breaks each preclinical finding out by lane — the BPC-157 tendon and angiogenesis studies, the TB-500 / Thymosin Beta-4 actin and wound-healing studies — and flags every blend-level gap. The research dosing context covers the animal-model doses, reconstitution and half-life, and the routes studied, with the honest note that no validated blend dose exists. The FAQ collects the safety and the tumor-signal concern. Every quantitative claim resolves to the full reference list.
The register here is deliberately sober. The negative space on this manifest — no controlled blend trial, no validated dose, an identity caveat that doubles inside the pairing — is itself part of the record, and it is logged in the same ink as the findings.